| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
851.46(B) |
| Last
Volume: |
2,877,071 |
Avg
Vol: |
3,271,395 |
| 52
Week Range: |
$434.7 - $891.46 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
1,332,477 |
2,203,227 |
3,639,104 |
6,172,895 |
| Total Sell Value |
$1,114,649,593 |
$1,722,900,173 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
17 |
30 |
51 |
94 |
| End Date |
2024-03-26 |
2023-12-24 |
2023-06-25 |
2022-06-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2019-12-06 |
4 |
AS |
$120.00 |
$540,000 |
D/D |
(4,500) |
29,306 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-12-06 |
4 |
S |
$120.15 |
$23,313,498 |
D/D |
(194,038) |
115,026,266 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-12-04 |
4 |
S |
$118.52 |
$24,890,040 |
D/D |
(210,000) |
115,220,304 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-11-27 |
4 |
S |
$117.51 |
$5,752,257 |
D/D |
(48,953) |
115,430,304 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-11-25 |
4 |
S |
$117.60 |
$12,855,797 |
D/D |
(109,318) |
115,535,986 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-11-22 |
4 |
S |
$115.74 |
$29,263,596 |
D/D |
(251,736) |
115,645,304 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-11-21 |
4 |
S |
$115.14 |
$12,465,506 |
D/D |
(108,264) |
115,897,040 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-11-19 |
4 |
S |
$114.99 |
$23,586,776 |
D/D |
(205,000) |
116,005,304 |
|
- |
|
| Walker Karen |
Director |
– • – |
2019-11-18 |
4 |
A |
$114.07 |
$192,436 |
D/D |
1,687 |
2,834 |
|
- |
|
| Runge Marschall S |
Director |
– • – |
2019-11-18 |
4 |
A |
$114.07 |
$174,983 |
D/D |
1,534 |
12,779 |
|
- |
|
| Jackson Jamere |
Director |
– • – |
2019-11-18 |
4 |
A |
$114.07 |
$174,983 |
D/D |
1,534 |
5,629 |
|
- |
|
| Eskew Michael L |
Director |
– • – |
2019-11-18 |
4 |
A |
$114.07 |
$174,983 |
D/D |
1,534 |
41,610 |
|
- |
|
| Baicker Katherine |
Director |
– • – |
2019-11-18 |
4 |
A |
$114.07 |
$174,983 |
D/D |
1,534 |
18,687 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2019-11-18 |
4 |
A |
$114.07 |
$185,934 |
D/D |
1,630 |
46,580 |
|
- |
|
| Seifert Kathi P |
Director |
– • – |
2019-11-18 |
4 |
A |
$114.07 |
$174,983 |
D/D |
1,534 |
74,337 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2019-11-18 |
4 |
A |
$114.07 |
$188,558 |
D/D |
1,653 |
10,991 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2019-11-18 |
4 |
A |
$114.07 |
$177,037 |
D/D |
1,552 |
57,992 |
|
- |
|
| Bertozzi Carolyn R |
Director |
– • – |
2019-11-18 |
4 |
A |
$114.07 |
$174,983 |
D/D |
1,534 |
4,905 |
|
- |
|
| Kaelin William G Jr |
Director |
– • – |
2019-11-18 |
4 |
A |
$117.07 |
$179,585 |
D/D |
1,534 |
17,139 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2019-11-18 |
4 |
A |
$114.07 |
$174,983 |
D/D |
1,534 |
64,254 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-11-18 |
4 |
S |
$114.00 |
$1,208,172 |
D/D |
(10,598) |
116,210,304 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-11-12 |
4 |
S |
$114.00 |
$909,841 |
D/D |
(7,981) |
116,220,902 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-11-11 |
4 |
S |
$114.07 |
$11,407 |
D/D |
(100) |
116,228,883 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-11-07 |
4 |
S |
$114.37 |
$45,749 |
D/D |
(400) |
116,228,983 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-11-06 |
4 |
S |
$114.05 |
$19,835,000 |
D/D |
(173,918) |
116,229,383 |
|
- |
|
1436 Records found
|
|
Page 26 of 58 |
|
|
6.23 (0.7%) 
